News Features PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data Michael O'Riordan January 25, 2016
News Features Increased Early Risk of Stent Thrombosis With the Absorb Bioresorbable Scaffold Michael O'Riordan January 06, 2016
News Features The Bioresorbable Stent Story So Far: What Promise? What Price? Michael O'Riordan August 17, 2016
News Features Brooding Over Brexit: Cardiologists Voice Uncertainty About Effects on Collaboration, Research Funding Yael L. Maxwell June 29, 2016
News Features Cardiologists Grapple With AI-Generated Content in Slides Yael L. Maxwell October 26, 2026
News Features Holding Out Hope for HF Shunts, Even After an FDA Panel’s Doubts Michael O'Riordan February 24, 2026
News Features Clots Found in the Left Atrial Appendage: A Big Deal for TAVR? Todd Neale June 27, 2016
News Features La Innovación en Tecnologías Stent es Posible y algo que Merece la Pena Perseguir Todd Neale November 08, 2015
News Features From Great to Greater: Innovation in Stent Technology Possible, Worth Pursuing Todd Neale November 08, 2015
News Features Posibles Luchas Territoriales sobre Cómo Administrar las Intervenciones en el Manejo de ACV Agudos Todd Neale December 28, 2015
News Features Possible Turf War Brewing Over Delivery of Acute Stroke Interventions Todd Neale December 28, 2015
News Features Imperfect Evidence: How Strong Is the Case for Transcatheter Tricuspid Valve Interventions? Todd Neale October 22, 2025
News Features Cardiac Transplant in Midst of ‘Revolution,’ but Public Trust Is Fragile Michael O'Riordan October 17, 2025
News Features ‘Buzz and Discussion’ Driving Return to In-Person Cardiology Meetings Michael O'Riordan September 17, 2025
News Features Digesting the Valve Degeneration Data: One Month Later, Reactions From TAVR Experts Range From ‘Disturbed’ to Indifferent Caitlin E. Cox June 17, 2016
News Features What’s in a Name: Is It Time to Choose Between TAVI and TAVR? Yael L. Maxwell March 27, 2025